Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson's Disease in Patients with Type 2 Diabetes: A Population-Based Cohort Study.
GLP-1 受體激動劑與 2 型糖尿病患者帕金森病風險:一項基於人群的隊列研究。
Mov Disord 2024-08-27
Do oral antidiabetic medications alter the risk of Parkinson's disease? An updated systematic review and meta-analysis.
口服抗糖尿病藥物是否改變帕金森氏症的風險?一項更新的系統性回顧和荟萃分析。
Neurol Sci 2023-11-22
Meta-analysis of Association between Newer Glucose-Lowering Drugs and Risk of Parkinson's Disease.
新型降糖藥物與帕金森氏症風險之間的關聯的荟萃分析。
Mov Disord Clin Pract 2024-02-10
Use of dipeptidyl peptidase-4 inhibitors was associated with a lower risk of Parkinson's disease in diabetic patients.
糖尿病患者使用二肽基胜肽酶-4抑制劑與帕金森病風險降低相關。
Sci Rep 2023-12-28
Glucagon-Like Peptide-1 Receptor Agonists and Pancreatic Cancer Risk in Patients With Type 2 Diabetes.
二型糖尿病患者中胰臟癌風險與葡萄糖樣肽-1受體激動劑的關聯。
JAMA Netw Open 2024-01-08
The Use of Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus Does Not Increase the Risk of Pancreatic Cancer: A U.S.-Based Cohort Study.
糖尿病患者使用 GLP-1 受體激動劑不會增加胰臟癌風險:美國基礎的世代研究。
Cancers (Basel) 2024-05-13
Sodium-glucose cotransporter 2 inhibitors and the risk of Parkinson disease in real-world patients with type 2 diabetes.
鈉-葡萄糖共轉運蛋白 2 抑制劑與實際世界中 2 型糖尿病患者罹患帕金森病的風險。
Diabetes Obes Metab 2024-09-11
Anti-diabetic drug use and reduced risk of Parkinson's disease: A community-based cohort study.
抗糖尿病藥物使用與帕金森病風險降低:一項社區基礎的隊列研究。
Parkinsonism Relat Disord 2024-09-11
SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes.
SGLT2 抑制劑使用與 2 型糖尿病患者罹患癡呆症和帕金森病的風險。
Neurology 2024-09-18
Comparative outcomes of systemic diseases in people with type 2 diabetes, or obesity alone treated with and without GLP-1 receptor agonists: a retrospective cohort study from the Global Collaborative Network : Author list.
使用與不使用 GLP-1 受體激動劑治療的 2 型糖尿病或僅肥胖患者的系統性疾病比較結果:來自全球合作網絡的回顧性隊列研究:作者列表。
J Endocrinol Invest 2024-09-20